Drugs / regulatory T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03284242 | Mar 2019 → Apr 2024 | end stage renal failure | Roberto Gedaly | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | regulatory T cells | “regulatory T cells” NCT03284242 ↗ |
| Known as | Treg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03284242 ↗ |
| Modality | Cell therapy | “ex vivo expanded autologous Treg cells as an adoptive cellular therapy” PMID 30451741 ↗ Apr 2019 |
| Route | Intravenous | “This will be a single intravenous (IV) infusion.” NCT03284242 ↗ |